Ariana Jimenez

Ms. Ariana Jimenez

University of Georgia - Athens
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2020 in Viruses
Verified
Journal Article
Open access
PDF file
KHKatherine Elizabeth Havranek
Katherine Elizabeth Havranek
AJAriana Jimenez
Ariana Jimenez
MAMarissa Acciani
Marissa Acciani
MMMaria Fernanda Lay Mendoza
Maria Fernanda Lay Mendoza
JBJudith Reyes Ballista
Judith Reyes Ballista
Melinda BrindleyMelinda Brindley
Melinda Brindley
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the most recent global pandemic that has caused more than a million deaths around the world. The spike glycoprotein (S) drives the entry and fusion of this virus and is the main determinant of cell tropism. To explore S requirements for entry under BSL2 conditions, S has been pseudotyped onto vesicular stomatitis virus (VSV) or retroviral particles with varied success. Several alterations to S were demonstrated to improve pseudoparticle titers, but they have not been systematically compared. In this study, we produced pseudotyped VSV particles with multiple modifications to S, including truncation, mutation, and tagging strategies. The main objective of this study was to determine which modifications of the S protein optimize cell surface expression, incorporation into pseudotyped particles, and pseudoparticle entry. Removal of the last 19 residues of the cytoplasmic tail produced a hyper-fusogenic S, while removal of 21 residues increased S surface production and VSV incorporation. Additionally, we engineered a replication-competent VSV (rVSV) virus to produce the S-D614G variant with a truncated cytoplasmic tail. While the particles can be used to assess S entry requirements, the rVSV∆G/SMet1D614G∆21 virus has a poor specific infectivity (particle to infectious titer ratio).

17 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAidan C. Manning
Aidan C. Manning
MBMahmoud M. Bashir
Mahmoud M. Bashir
AJAriana Jimenez
Ariana Jimenez
HUHeather E. Upton
Heather E. Upton
KCKathleen Collins
Kathleen Collins
JTJessica Mitchell Tucker
Jessica Mitchell Tucker
Withdrawal statement: The authors have withdrawn this manuscript due to a duplicate posting of manuscript number BIORXIV/2024/592122. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author. The correct preprint can be found at doi: https://doi.org/10.1101/2024.05.01.592122 .

10 September 2026 in Journal of Experimental Medicine
Verified
Journal Article
Open access
SMSarah E. Michalets
Sarah E. Michalets
YSYixel Soto-Vazquez
Yixel Soto-Vazquez
KMKathryn M. Moore
Kathryn M. Moore
MWM. Elliott Williams
M. Elliott Williams
ASAnanya Saha
Ananya Saha
JKJacob E. Kohlmeier
Jacob E. Kohlmeier
Intranasal vaccination elicits CD8 tissue-resident memory T cells (TRM) throughout the respiratory tract that provide cross-protection against heterosubtypic viral strains and reduce immunopathology. We previously demonstrated that CD8 TRM can reduce the probability of respiratory virus transmission and the magnitude of infection, using a murine model of parainfluenza virus transmission. Here, we show that CD8 TRM-mediated protection occurs independently of circulating leukocytes, B cells, or CD4 T cells. Additionally, we investigate the contributions of CD8 TRM in different respiratory tract compartments and illustrate that CD8 TRM in the upper respiratory tract (URT), but not the lower respiratory tract (LRT), become activated and proliferate in response to transmitted virus. Furthermore, we demonstrate that CD8 TRM in the URT alone provide sufficient immune surveillance to prevent propagation of infection after viral transmission. These findings offer insights into the development of T cell–based respiratory virus vaccines and shed light on the critical role of URT CD8 TRM in the prevention of viral transmission.